Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Carina Nebula shines with white-blue stars | Space photo of the day for Jan. 5, 2026 - 2Air travelers face higher ticket prices as Iran war drives up oil prices
- 3The Most Compelling Innovation Developments Somewhat recently
- 4How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV
- 5Ukrainian drones hit all three Baltic States − did Russia redirect them?
- Catch the moon dancing with bright star Regulus tonight
- Supercharge Your Remote Work Arrangement with These Game-Changing Instruments
- 6 Exemplary Mexican Dishes
- 'Spending more on gas than groceries:' Rising fuel prices drive more San Antonio families to the Food Bank amid Iran war
- The most effective method to Guarantee Simple Availability in Seniors' SUVs
- Google to Use Natural Gas to Power Massive Data Center in Texas
- Manual for extravagance SUVs for seniors
- 6 Objections for an Ocean side Wedding
- EU calls on Western Balkans to step up reforms for membership
